STALICLA
  1. Companies
  2. STALICLA
  3. Videos
  4. Stalicla - Model & Platform - Video

Stalicla - Model & Platform - Video

SHARE

How is STALICLA categorizing subgroups of patients with Autism?

STALICLA leverages on its proprietary drug-discovery platform to bring personalized medicine to patients with autism and other ill-defined NDDs. This platform is called called DEPI: Databased Endophenotyping Patient Identification. DEPI analyses vast amounts of anonymized data from large cohorts of patients with ASD, including clinical data, genetic data, and other complex biological data. By identifying patterns and links in this information, DEPI can help differentiate the patients into more-homogeneous subgroups.

This is the first step away from a one-size-fits-all approach, and towards personalized treatment options for patients who feel impaired by the symptoms of their condition.

Most popular related searches